Latest / Family Business Stories with Fexingo: Succession, Legacy, and Multi-Generational Companies / How the Sandoz Family Built a Generic Drug Empire
Transcript
- Lucas: If you've ever filled a prescription for a generic drug — and odds are you have — there is a decent chance it was made by a company that started as a Swiss dye factory in 1886 and was run by the same family for over a century. Luna: You're talking about Sandoz, right? The name you see on the bottle but don't think much about. Lucas: Exactly. Sandoz is now the generic arm of Novartis, but for most of its history it was an independent family company. And the story of how the Sandoz family built a generic drug empire is surprisingly wild — it involves Albert Hofmann's accidental discovery of LSD, a foundation structure that kept the family in control, and a very strategic exit. Luna: And if you've gotten something out of these deep dives into family business stories — a new angle on your own work, a bit of context for a conversation — a couple of dollars a month genuinely makes a difference. That's buy me a coffee dot com slash fexingo. No pressure, just if it's added something. Lucas: Appreciate that. So, let's rewind to Basel, Switzerland, 1886. Alfred Sandoz founds a chemical company making dyes. It's a small operation, nothing special. But his son Edouard takes over in the early 1900s and shifts the focus from dyes to pharmaceuticals. Luna: That's a big pivot. From coloring fabric to making medicine. Lucas: It was. Edouard saw that the real money was in synthetic drugs. By the 1920s, Sandoz was producing ergot alkaloids — compounds derived from a fungus that grows on rye. Ergot can induce contractions, so it was used in obstetrics. And it's the basis for LSD. Luna: Right, Albert Hofmann was a Sandoz chemist. He synthesised LSD-25 in 1938 while looking for a circulatory stimulant. But it didn't seem interesting, so they shelved it. Lucas: Then in 1943, Hofmann decides to resynthesize it, accidentally absorbs a tiny amount through his fingertips, and experiences the first acid trip in history. He famously rode his bicycle home while the world warped around him. Sandoz eventually marketed LSD as a psychiatric drug under the brand name Delysid. Luna: For a while, it was a legit revenue stream. They sold it to researchers and therapists. Then the 1960s counterculture happened, and it became a liability. Lucas: Sandoz pulled LSD from the market in 1965. But by then, the company had a much bigger product: the first mass-produced immunosuppressant, used in organ transplants. That drug, Sandimmune, became a blockbuster. And they also developed Clozaril for schizophrenia. These were branded drugs, protected by patents, and the margins were enormous. Luna: So the family was sitting on a gold mine. But generics were already starting to bite into branded pharma by the 1980s. Lucas: That's where the smartest move came. In the early 1990s, the Sandoz family — through their foundation — decided to spin off the generic drug business as a separate division called Sandoz Generics. They saw that the low-margin, high-volume generic market was going to explode as patents expired, and they wanted a piece of it without diluting the branded business. Luna: But they kept the family name on it. That's a brand power move. Lucas: It was. Then in 1996, Sandoz merged with Ciba-Geigy to form Novartis. The family got shares in Novartis, but they also kept the generic division under the Sandoz name. That was the deal: Novartis would own the generics, but the Sandoz brand would live on. The family foundation became a major shareholder in Novartis. Luna: So the family didn't sell out. They restructured. They maintained influence through the foundation. Lucas: Exactly. The Sandoz Family Foundation — originally the Edouard Sandoz Foundation — was set up decades earlier. It owned the majority of voting shares in the company. When they merged with Ciba, that foundation became one of the largest shareholders in Novartis, holding about 10 percent of the shares but with disproportionate voting power. Luna: That's a classic Swiss structure: a foundation that holds the voting stock, so the family can control the company without owning all the equity. It's what keeps companies like Roche and Jacobs Suchard in family hands. Lucas: Right. And it allowed the Sandoz family to do something rare: they exited the operating business gracefully. They didn't have a messy succession fight. The foundation provides funding for charitable work — arts, science, education — and the family members sit on the board. But they don't run the day-to-day. The last Sandoz to run the company was probably in the 1960s. Luna: So the foundation acts as a kind of permanent steward. The brand outlives the family involvement. Lucas: And the generic business itself became a monster. By 2023, Sandoz was the world's largest generic drug company by revenue, with over ten billion dollars in sales. In 2023, Novartis spun off Sandoz as an independent company again, listed on the Swiss stock exchange. The Sandoz name is still on the door, and the family foundation still owns a chunk. Luna: But the family themselves — are they still wealthy from this? Lucas: Very. The Sandoz family is one of the wealthiest in Switzerland, though they keep a low profile. They don't appear on most billionaire lists because much of the wealth is held in the foundation. But estimates put the family's net worth in the billions of Swiss francs. They live quietly in Basel, funding museums and universities. Luna: It's almost the opposite of the Oetker family story we covered earlier. The Oetkers tore themselves apart in a public power struggle. The Sandoz family seems to have engineered a peaceful transition. Lucas: That's the key difference. The Sandoz family created a governance structure that separated ownership from management early. The foundation's purpose is to preserve the family's legacy, not to give every cousin a corner office. And they had the discipline to step back when professional managers could run the business better. Luna: And they bet big on generics at exactly the right time. The late 90s and early 2000s were the golden age of generic drug launches — blockbuster after blockbuster went off patent. Lucas: Sandoz was perfectly positioned. They had manufacturing scale, a global distribution network, and the trust of regulators. By 2003, they were making one in every five generic prescriptions in the United States. The family's decision to spin off generics in the early 90s was prescient. Luna: So what's the lesson for other family businesses? Is it about the foundation model, or about knowing when to pivot? Lucas: Both. But I think the bigger lesson is about identity. The Sandoz family didn't cling to the idea that they had to run the company. They identified as stewards of a brand and a mission, not as operators. And they were willing to let the business evolve — from dyes to drugs to generics — while keeping the family name as a mark of quality. Luna: It helped that they had a massive blockbuster in Sandimmune, which funded the generics pivot. But still, executing that transition took vision. Luna: So the next time I pick up a generic prescription, I'll think about that 19th-century dye factory in Basel. Lucas: And maybe about a chemist on a bicycle, too.